Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Front Immunol. 2024 Oct 24;15:1462346. doi: 10.3389/fimmu.2024.1462346. eCollection 2024.
This study explores the benefits of targeted-immunotherapy combination in third-line or beyond treatment for microsatellite stable (MSS) metastatic colorectal cancer (mCRC) in a real-world setting.
Patients with MSS mCRC who were treated with either a targeted-immunotherapy combination or targeted therapy alone in the third-line or beyond setting at our hospital from August 2018 to August 2022 were included in the study. Inclusion criteria comprised patients treated with targeted therapy alone or in combination with immunotherapy. Effectiveness was compared between treatments, and patients with the potential to benefit from targeted-immunotherapy combination were identified.
Among 71 patients, 31 received targeted therapies alone (TT group) and 40 received a combination of targeted therapy and immunotherapy (TI group). The TI group had higher objective response rates (20% vs 3.2%) and disease control rates (82.5% vs 58.1%). The median progression-free survival was significantly better in the TI group (4.6 vs 4.1 months, P = 0.027). Liver metastasis was associated with poor prognosis, while patients with only lung metastases had the longest median progression-free survival of 12.3 months with combination therapy.
The study indicates that targeted-immunotherapy combination offers more benefits than targeted therapy alone for MSS mCRC in the third-line or beyond setting.
本研究旨在探讨在真实世界环境中，针对微卫星稳定（MSS）转移性结直肠癌（mCRC）三线或以上治疗中，靶向免疫联合治疗的获益。
本研究纳入了 2018 年 8 月至 2022 年 8 月期间在我院接受三线或以上治疗的 MSS mCRC 患者，这些患者接受了靶向免疫联合治疗或靶向单药治疗。纳入标准为接受靶向单药或联合免疫治疗的患者。比较了两种治疗方案的疗效，并确定了可能从靶向免疫联合治疗中获益的患者。
在 71 例患者中，31 例接受了靶向单药治疗（TT 组），40 例接受了靶向联合免疫治疗（TI 组）。TI 组的客观缓解率（20%比 3.2%）和疾病控制率（82.5%比 58.1%）更高。TI 组的中位无进展生存期显著更长（4.6 个月比 4.1 个月，P = 0.027）。肝转移与预后不良相关，而仅发生肺转移的患者接受联合治疗的中位无进展生存期最长，为 12.3 个月。
本研究表明，对于 MSS mCRC 三线或以上治疗，靶向免疫联合治疗优于靶向单药治疗。
